[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Carefusion 2200 Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":77},{"warningLetters":4,"total":76},[5,32,55],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},180,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-05-05T04:00:00Z\">05\u002F05\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-30T04:00:00Z\">04\u002F30\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcarefusion-213-llc-722729-04302026\">CareFusion 213, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-72\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Thomas E. Polen, Jr.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman, CEO and President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>CareFusion 213, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1 Becton Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Franklin Lakes\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07417-1880\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-72\u003C\u002Fp>\u003Cp>April 30, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Polen:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, CareFusion 213, LLC (a wholly-owned subsidiary of Becton, Dickinson and Company (BD)), FEI 3004932373, at 1550 Northwestern Drive, El Paso, Texas, from October 15 to 24, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your November 17, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures sterile drug products for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which are used \u003Cstrong>(b)(4)\u003C\u002Fstrong>. \u003Cstrong>(b)(4)\u003C\u002Fstrong> is also specifically labeled for use in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your manufacturing process includes sterilizing the drug solution in sealed \u003Cstrong>(b)(4)\u003C\u002Fstrong> ampoules. Some \u003Cstrong>(b)(4)\u003C\u002Fstrong> undergo \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Complaint Investigations\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Since September 2023, your firm has received more than 2,500 customer complaints about your drug products including reports of foreign matter (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles and suspected mold), missing components, empty \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and compromised package seals. Your investigations into these complaints were inadequate, as you repeatedly failed to conduct thorough investigations, adequately identify root causes, provide scientific rationale for your conclusions, and extend investigations to other potentially affected batches. As a result, your corrective actions and preventive actions (CAPAs) were ineffective.\u003C\u002Fp>\u003Cp>For example, your investigation into a complaint of black specks and possible mold on sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> was deficient. You concluded the most likely root cause was the unintentional introduction of particulate matter from the manufacturing environment, yet you failed to extend the investigation to other lots that were manufactured under the same conditions or on the same equipment. Additionally, your investigation did not sufficiently examine potential contributing factors such as facility and equipment cleaning and maintenance, and personnel practices. Your investigation concluded that “a project has been opened to further investigate the reported issue,” but you lacked evidence that the follow-up project was actually initiated.\u003C\u002Fp>\u003Cp>Furthermore, your investigation into a complaint identifying \u003Cstrong>(b)(4)\u003C\u002Fstrong> pieces, missing \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and illegible printing on your \u003Cstrong>(b)(4)\u003C\u002Fstrong> was also inadequate. You indicated that the probable root cause of \u003Cstrong>(b)(4)\u003C\u002Fstrong> pieces and missing \u003Cstrong>(b)(4)\u003C\u002Fstrong> was equipment vibrations during manufacturing, but you did not extend the investigation to other batches processed on the same equipment. Your investigation also did not address the illegible printing on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> identified in the complaint.\u003C\u002Fp>\u003Cp>FDA investigators observed numerous other examples in which your firm failed to conduct thorough investigations related to complaints, including failing to follow investigation procedures, failing to extend investigations to other potentially impacted batches, and failing to conduct appropriate market action assessments.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Out-of-Specification (OOS) Investigations and CAPA\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your OOS investigations and CAPA were deficient. For example, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed a sterility test during stability testing. You initiated a recall and concluded that \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to seal the \u003Cstrong>(b)(4)\u003C\u002Fstrong> caused the sterility failure. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> created \u003Cstrong>(b)(4)\u003C\u002Fstrong> that compromised the sterile barrier. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> supplier informed you that \u003Cstrong>(b)(4)\u003C\u002Fstrong> are inherent and cannot be entirely eliminated, and you determined that you had no in-process inspection criteria for \u003Cstrong>(b)(4)\u003C\u002Fstrong> defects.\u003C\u002Fp>\u003Cp>Although your investigation examined other batches manufactured with the same lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and identified \u003Cstrong>(b)(4)\u003C\u002Fstrong> in multiple batches, you failed to properly extend your investigation to batches manufactured with other lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> from the same supplier. Notably, the investigation failed to address the scope and severity of a container-closure integrity issue that led to non-sterility and a product recall. Your quality system did not ensure that systemic problems with both the \u003Cstrong>(b)(4)\u003C\u002Fstrong> material and your inspection process were addressed by a comprehensive CAPA.\u003C\u002Fp>\u003Cp>In your response, you state that you have engaged a consultant to perform a comprehensive review of your quality system, revised your standard operating procedures for complaint handling, implemented an enhanced training program for complaint investigators and quality personnel, and are conducting a retrospective review of past complaints. Regarding the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterility failure, you state that you extended your investigation to all \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots, inspected retain samples, found additional \u003Cstrong>(b)(4)\u003C\u002Fstrong> but no sterility failures, and concluded the failure was isolated to the recalled lot.\u003C\u002Fp>\u003Cp>Your response is inadequate. You have not adequately explained how your quality unit failed in its oversight of numerous investigations associated with repeated and systemic product quality deficiencies that led to customer complaints. Your conclusion that the sterility failure was isolated to one incoming \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot is contradicted by the supplier’s statements that \u003Cstrong>(b)(4)\u003C\u002Fstrong> are inherent to their process and cannot be eliminated. You do not sufficiently address how you will detect when this inherent material attribute causes breaches in container-closure integrity to ensure that defective units are not distributed.\u003C\u002Fp>\u003Cp>Regarding the recall, you performed your extended investigation only after FDA identified significant gaps in the original investigation. You do not discuss why you did not initially extend your investigation when you identified systemic issues with the packaging material.\u003C\u002Fp>\u003Cp>We note that your firm has a history of sterility-related quality issues including multiple recalls and Field Alert Reports. It is essential that you assure sterility of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> products.\u003C\u002Fp>\u003Cp>To ensure proper root cause analysis and appropriate CAPA implementation, investigations must be thorough, well-documented, scientifically sound, and timely. Procedural updates and training alone do not address the systemic failures that allowed deficient investigations to persist undetected by quality unit oversight.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\u003C\u002Fli>\u003Cli>A comprehensive, independent retrospective review of all complaint investigations for the last three years from the initial date of inspection. In particular, this review should prioritize critical complaints relating to foreign contamination, container-closure integrity, non-integral products (e.g., missing \u003Cstrong>(b)(4)\u003C\u002Fstrong>), functionality problems, and potential sterility issues. Include the following independent assessment for each investigation:\u003Cbr>o Determine whether the scientific justification and evidence relating to the identified root cause(s) were adequately documented. Where a complaint was attributed to factors outside of the firm’s control (e.g., user error), assess the strength of this determination and whether it was based on conclusive or inconclusive information.\u003Cbr>o Determine whether relevant complaint samples were available and the extent of efforts to obtain the complaint sample from the complainant. If insufficient attempts were made, identify the root cause(s) for not adequately pursuing their return.\u003Cbr>o For all complaint investigations found by the retrospective review to be deficient, to have an inconclusive root cause, or to have no root cause identified, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, OOS history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation and any identified CAPA (e.g., manufacturing operation improvements).\u003Cbr>o Identify any patterns or trends across complaints that may indicate systemic manufacturing, quality control, supplier qualification, or design issues requiring corrective action.\u003Cbr>o Based upon this independent review, provide a comprehensive assessment of your overall complaint handling program that identifies any deficiencies and corresponding CAPA.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOS-result investigation systems. The CAPA should include but not be limited to addressing the following:\u003Cbr>o Quality unit oversight of laboratory investigations\u003Cbr>o Identification of adverse laboratory control trends\u003Cbr>o Resolution of causes of laboratory variation\u003Cbr>o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>o Adequate scoping of each investigation and its CAPA\u003Cbr>o Revised OOS investigation procedures with these and other remediations\u003C\u002Fli>\u003Cli>Provide a comprehensive, independent review of your process capability and quality performance, including:\u003Cbr>o Comprehensive identification of all defects encountered at each manufacturing process stage.\u003Cbr>o Classification of each identified defect by type, frequency (i.e., average, range), severity, and root cause(s).\u003Cbr>o Analysis of multi-year, longitudinal batch-to-batch trending data for each defect.\u003Cbr>o Actual in-process and finished product yield data for each batch.\u003Cbr>o Process capability index calculations for all critical manufacturing steps.\u003Cbr>o A thorough independent assessment of both sporadic (i.e., unexpected spikes) and average variability observed based upon detailed review of above items. Provide analytical findings, associated operational weaknesses and root causes, and potential remediation options.\u003C\u002Fli>\u003Cli>Your commitment to implement CAPA based on the above process performance analysis and to begin conducting annual capability analysis with quality oversight across all product lines.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm lacked appropriate spore population verification on in-house prepared biological indicators (BIs) used in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization \u003Cstrong>(b)(4)\u003C\u002Fstrong> process. You used these BIs for verifying sterilization effectiveness and as a batch release specification for \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products.\u003C\u002Fp>\u003Cp>You validated your method for preparing BIs for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> process in 2015 and included a target specification for \u003Cstrong>(b)(4)\u003C\u002Fstrong> spores of \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units (CFU). However, you have failed to perform quantitative verification of the spore population for these BIs since the initial validation. Instead, your firm has relied on a combination of vendor certificates for the initial spore count, theoretical calculations, and qualitative (growth\u002Fno growth) testing after \u003Cstrong>(b)(4)\u003C\u002Fstrong> with the final prepared BIs to evaluate sterilization effectiveness. Your procedure for preparing BIs states that population verification is not required because the preparation method was validated. However, validation of a preparation method does not eliminate the need for ongoing verification.\u003C\u002Fp>\u003Cp>In your response, you state that you have subsequently performed verification studies on recent BI preparations, and you commit to implementing ongoing verification. You also state that there is no impact to finished products because your \u003Cstrong>(b)(4)\u003C\u002Fstrong> parameters are set to ensure the reproducibility of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process.\u003C\u002Fp>\u003Cp>Your response is inadequate because you did not assess the impact of the lack of quantitative verification of your BIs. Your assertion of \u003Cstrong>(b)(4)\u003C\u002Fstrong> process reproducibility assumes the BIs consistently contained adequate spore populations, which you have not demonstrated.\u003C\u002Fp>\u003Cp>Without quantitative verification, you cannot determine whether “no growth” results after \u003Cstrong>(b)(4)\u003C\u002Fstrong> are due to an effective sterilization cycle or are because the BIs are lacking sufficient viable spore population.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>For any \u003Cstrong>(b)(4)\u003C\u002Fstrong> products that are not terminally sterilized by your company (or its contract facilities), explain whether you distribute these unsterilized products with the expectation that your customers will ultimately perform terminal sterilization of these batches.\u003C\u002Fli>\u003Cli>A comprehensive plan and timeline to transition all \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products to terminal sterilization. If your firm does not intend to transition all \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products to terminal sterilization, provide a detailed rationale justifying your scientific and public health basis. Also include a risk assessment that addresses your history of sterility-related quality issues.\u003C\u002Fli>\u003Cli>A comprehensive process description for all \u003Cstrong>(b)(4)\u003C\u002Fstrong> products your firm distributes. When describing each of the process options that your firm can use, detail whether the \u003Cstrong>(b)(4)\u003C\u002Fstrong> finished product is sterilized. For any process option that does not involve \u003Cstrong>(b)(4)\u003C\u002Fstrong> (including \u003Cstrong>(b)(4)\u003C\u002Fstrong>) prior to sterilization, comprehensively describe the \u003Cstrong>(b)(4)\u003C\u002Fstrong> steps that occur following the interim sterilization step. Also explain whether \u003Cstrong>(b)(4)\u003C\u002Fstrong> are sterilized, and if not, what your microbial bioburden specifications are for these parts and under what cleanroom conditions \u003Cstrong>(b)(4)\u003C\u002Fstrong> occurs.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment; and failed to perform operations within specifically defined areas of adequate size; and failed to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups (21 CFR 211.67(b) and 21 CFR 211.42(c)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During our inspection, we observed inadequate cleaning and inadequate contamination control throughout your manufacturing facility where sterile drug products are assembled and packaged.\u003C\u002Fp>\u003Cp>For example, our investigators found \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> inside your \u003Cstrong>(b)(4)\u003C\u002Fstrong> chambers which sterilize your drug product ampoules. During the inspection, your firm confirmed that the chamber cleaning procedure involved \u003Cstrong>(b)(4)\u003C\u002Fstrong> the \u003Cstrong>(b)(4)\u003C\u002Fstrong> chambers \u003Cstrong>(b)(4)\u003C\u002Fstrong> to remove \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, we noted multiple instances of your operators’ failure to appropriately document \u003Cstrong>(b)(4)\u003C\u002Fstrong> during a period when multiple U.S. batches were being sterilized. Additionally, you did not test the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> process for chemical or microbiological specifications. Unsuitable \u003Cstrong>(b)(4)\u003C\u002Fstrong> quality could introduce \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and bioburden – further compromising chamber cleanliness and sterilization efficacy.\u003C\u002Fp>\u003Cp>FDA investigators observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> residue on air vents, walls, and equipment surfaces in your main production area, packaging lines, ampoule rinsing room, and equipment washroom, despite cleaning logs documenting these areas had been cleaned. FDA investigators also observed broken \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong> with sterilized ampoules next to assembly lines where these ampoules are \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your contamination control practices were also inadequate. FDA investigators observed personnel wearing face masks improperly in violation of your gowning procedures. Your quality notification QN 201162939 documented a bioburden excursion in non-sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> product showing \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU with \u003Cem>Streptococcus pneumoniae\u003C\u002Fem> identified, a significant opportunistic pathogen commonly found in the nose and throat.\u003C\u002Fp>\u003Cp>Multiple environmental monitoring (EM) excursions also occurred in your filling areas. These contamination control failures are particularly worrisome if your \u003Cstrong>(b)(4)\u003C\u002Fstrong> do not ultimately undergo terminal sterilization on the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. When terminal sterilization is not applied to the finished product, robust aseptic processing control becomes critical to ensuring product sterility.\u003C\u002Fp>\u003Cp>Notably, robust manufacturing design and control to prevent contamination also applies if \u003Cstrong>(b)(4)\u003C\u002Fstrong> are not intended to be sterile, when appropriate based on their indication. Such products must be free of microbes that may be objectionable in view of their intended use.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>Your response states that you engaged an independent third-party expert to review and redesign your cleaning validation program and committed to implementing cleaning validation for equipment and product-contact surfaces. You identified the \u003Cstrong>(b)(4)\u003C\u002Fstrong> residue as \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in certain \u003Cstrong>(b)(4)\u003C\u002Fstrong> and stated you evaluated chromatography data to confirm the absence of cross-contamination to other products. You conducted a risk assessment of your cleaning program and concluded that existing process controls at various manufacturing stages would detect and reject products containing residues, contaminants, or microorganisms beyond acceptable limits.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your commitment to implement cleaning validation does not address products currently in distribution manufactured under the conditions documented during the inspection. Your conclusion that existing controls would robustly detect contamination is contradicted by the nature of the customer complaints received by your firm, particularly given the extent of contamination, debris, gowning violations, and EM excursions documented during the inspection. Additionally, your identification of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> residue and review of chromatography data do not address why your cleaning procedures failed to prevent its accumulation.\u003C\u002Fp>\u003Cp>Inadequate removal of debris and residues from manufacturing equipment during cleaning can lead to contamination of drug products subsequently manufactured on the equipment. In addition, inadequate operational controls to prevent contamination can jeopardize patient safety by potentially compromising the sterility of products designed to \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your bioburden control program for non-sterile components and finished drug products. This assessment should include:\u003Cbr>o Bioburden testing and trending data for each lot of incoming \u003Cstrong>(b)(4)\u003C\u002Fstrong> received over the last three years, including total aerobic microbial count (TAMC), total yeast and mold count (TYMC), as well as all identification testing performed and organisms detected.\u003Cbr>o Bioburden and sterility testing data for all finished product batches manufactured over the last three years, including all data obtained when testing in-process and finished product batch units, as well as complete microbial identification of all organisms detected.\u003Cbr>o A comprehensive review by the independent third party of all microbiological test results (TAMC, TYMC, sterility tests, and organism identifications) for the last three years, including any OOS results that were subsequently invalidated. For any invalidated OOS results, assess the adequacy of the scientific justification and evidence supporting the invalidation decision.\u003Cbr>o An independent third-party review of your laboratory’s microbiological methods. The review should determine whether the methods are scientifically sound and capable of reliably detecting, quantifying, and identifying any bioburden present in incoming \u003Cstrong>(b)(4)\u003C\u002Fstrong> and finished drug products.\u003Cbr>o A summary report of all bioburden and sterility data collected from the above assessments, including trend analysis, identification of any patterns or excursions, and corresponding CAPA to address any deficiencies identified.\u003C\u002Fli>\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program including enhancements to cleaning effectiveness, improved ongoing verification of proper cleaning execution for all products and equipment, and all other needed remediations.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning validation program with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003Cbr>o drugs with higher toxicities\u003Cbr>o drugs with higher drug potencies\u003Cbr>o drugs of lower solubility in their cleaning solvents\u003Cbr>o drugs with characteristics that make them difficult to clean\u003Cbr>o swabbing locations for areas that are most difficult to clean\u003Cbr>o maximum hold times before cleaning\u003C\u002Fli>\u003Cli>Describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fli>\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>An independent, comprehensive review of your EM program to ensure vigilant, timely detection and response to potential product contamination hazards in your manufacturing environment. This assessment should include, but not be limited to:\u003Cbr>o establishing appropriate limits\u003Cbr>o sampling methods\u003Cbr>o sampling locations and frequencies\u003Cbr>o trend analysis\u003Cbr>o appropriate investigation of deviations and adverse trends\u003Cbr>o and a comprehensive CAPA plan based on the findings of the assessment\u003C\u002Fli>\u003Cli>A procedure for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring that specifies routine microbial and chemical testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure its acceptability for use in each batch of drug products produced by your firm, as well as its use in sterilization processes.\u003C\u002Fli>\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system.\u003C\u002Fli>\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> meeting appropriate chemical and microbial limits for use in \u003Cstrong>(b)(4)\u003C\u002Fstrong> process.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Assurance of Sterility – Terminal Sterilization\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>It should be noted that although the sterility test is a critical final quality control for \u003Cstrong>(b)(4)\u003C\u002Fstrong> finished products that purport to be sterile, it cannot be solely relied upon as justification to release each drug product batch. The sterility test is only the last in a series of design and control provisions intended to protect the consumer from distribution of an unsafe batch. Sample sizes for sterility testing are typically small compared to the total number of units in a batch and may not detect sporadic non-sterility. For example, a failure to consistently execute a terminal sterilization cycle of the finished product within its validated state, or a sporadic container-closure issue, may go undetected for substantial periods if your firm places too much reliance on the final quality control test for sterility to identify a sterility assurance problem. It is also essential to note that any positive sterility test result represents a serious CGMP issue that requires a comprehensive investigation into the cause and extent of the problem, and prompt review of the validated status of your terminal sterilization process.\u003C\u002Fp>\u003Cp>\u003Cstrong>Repeat Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In previous inspections occurring in 2023 and 2016, FDA has repeatedly cited similar CGMP observations. In 2016, FDA cited your firm for failure to perform adequate investigations of product failures. In 2023, FDA cited your firm for failure to ensure adequate laboratory controls and failure to maintain facilities in a good state of repair. The current inspection reveals these deficiencies have persisted or recurred, demonstrating that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Unit Authority\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Significant findings in this letter indicate that your quality unit is not fully exercising its authority and\u002For responsibilities. Your firm must provide the quality unit with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\u003C\u002Fp>\u003Cp>For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: \u003Cem>Q8(R2) Pharmaceutical Development\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload, \u003Cem>Q9(R1) Quality Risk Management\u003C\u002Fem> at\u003Cbr>https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167721\u002Fdownload, and \u003Cem>Q10 Pharmaceutical Quality System\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004932373 and ATTN: Bryce Hammer.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Return Receipt Requested\n\nReference #:\n\n320-26-72\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Thomas E. Polen, Jr.\n\nRecipient Title\n\nChairman, CEO and President\n\nCareFusion 213, LLC\n\n1 Becton Drive\n\nFranklin Lakes, NJ 07417-1880\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-72\nApril 30, 2026\nDear Mr. Polen:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, CareFusion 213, LLC (a wholly-owned subsidiary of Becton, Dickinson and Company (BD)), FEI 3004932373, at 1550 Northwestern Drive, El Paso, Texas, from October 15 to 24, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your November 17, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour firm manufactures sterile drug products for (b)(4), including (b)(4), which are used (b)(4). (b)(4) is also specifically labeled for use in (b)(4). Your manufacturing process includes sterilizing the drug solution in sealed (b)(4) ampoules. Some (b)(4) undergo (b)(4).\nInadequate Complaint Investigations\nSince September 2023, your firm has received more than 2,500 customer complaints about your drug products including reports of foreign matter (e.g., (b)(4) particles and suspected mold), missing components, empty (b)(4), and compromised package seals. Your investigations into these complaints were inadequate, as you repeatedly failed to conduct thorough investigations, adequately identify root causes, provide scientific rationale for your conclusions, and extend investigations to other potentially affected batches. As a result, your corrective actions and preventive actions (CAPAs) were ineffective.\nFor example, your investigation into a complaint of black specks and possible mold on sterile (b)(4) was deficient. You concluded the most likely root cause was the unintentional introduction of particulate matter from the manufacturing environment, yet you failed to extend the investigation to other lots that were manufactured under the same conditions or on the same equipment. Additionally, your investigation did not sufficiently examine potential contributing factors such as facility and equipment cleaning and maintenance, and personnel practices. Your investigation concluded that “a project has been opened to further investigate the reported issue,” but you lacked evidence that the follow-up project was actually initiated.\nFurthermore, your investigation into a complaint identifying (b)(4) pieces, missing (b)(4), and illegible printing on your (b)(4) was also inadequate. You indicated that the probable root cause of (b)(4) pieces and missing (b)(4) was equipment vibrations during manufacturing, but you did not extend the investigation to other batches processed on the same equipment. Your investigation also did not address the illegible printing on the (b)(4) identified in the complaint.\nFDA investigators observed numerous other examples in which your firm failed to conduct thorough investigations related to complaints, including failing to follow investigation procedures, failing to extend investigations to other potentially impacted batches, and failing to conduct appropriate market action assessments.\nInadequate Out-of-Specification (OOS) Investigations and CAPA\nYour OOS investigations and CAPA were deficient. For example, (b)(4) Lot (b)(4) failed a sterility test during stability testing. You initiated a recall and concluded that (b)(4) in the (b)(4) used to seal the (b)(4) caused the sterility failure. The (b)(4) created (b)(4) that compromised the sterile barrier. Your (b)(4) supplier informed you that (b)(4) are inherent and cannot be entirely eliminated, and you determined that you had no in-process inspection criteria for (b)(4) defects.\nAlthough your investigation examined other batches manufactured with the same lot of (b)(4) and identified (b)(4) in multiple batches, you failed to properly extend your investigation to batches manufactured with other lots of (b)(4) from the same supplier. Notably, the investigation failed to address the scope and severity of a container-closure integrity issue that led to non-sterility and a product recall. Your quality system did not ensure that systemic problems with both the (b)(4) material and your inspection process were addressed by a comprehensive CAPA.\nIn your response, you state that you have engaged a consultant to perform a comprehensive review of your quality system, revised your standard operating procedures for complaint handling, implemented an enhanced training program for complaint investigators and quality personnel, and are conducting a retrospective review of past complaints. Regarding the (b)(4) sterility failure, you state that you extended your investigation to all (b)(4) lots, inspected retain samples, found additional (b)(4) but no sterility failures, and concluded the failure was isolated to the recalled lot.\nYour response is inadequate. You have not adequately explained how your quality unit failed in its oversight of numerous investigations associated with repeated and systemic product quality deficiencies that led to customer complaints. Your conclusion that the sterility failure was isolated to one incoming (b)(4) lot is contradicted by the supplier’s statements that (b)(4) are inherent to their process and cannot be eliminated. You do not sufficiently address how you will detect when this inherent material attribute causes breaches in container-closure integrity to ensure that defective units are not distributed.\nRegarding the recall, you performed your extended investigation only after FDA identified significant gaps in the original investigation. You do not discuss why you did not initially extend your investigation when you identified systemic issues with the packaging material.\nWe note that your firm has a history of sterility-related quality issues including multiple recalls and Field Alert Reports. It is essential that you assure sterility of your (b)(4) products.\nTo ensure proper root cause analysis and appropriate CAPA implementation, investigations must be thorough, well-documented, scientifically sound, and timely. Procedural updates and training alone do not address the systemic failures that allowed deficient investigations to persist undetected by quality unit oversight.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\nA comprehensive, independent retrospective review of all complaint investigations for the last three years from the initial date of inspection. In particular, this review should prioritize critical complaints relating to foreign contamination, container-closure integrity, non-integral products (e.g., missing (b)(4)), functionality problems, and potential sterility issues. Include the following independent assessment for each investigation:\no Determine whether the scientific justification and evidence relating to the identified root cause(s) were adequately documented. Where a complaint was attributed to factors outside of the firm’s control (e.g., user error), assess the strength of this determination and whether it was based on conclusive or inconclusive information.\no Determine whether relevant complaint samples were available and the extent of efforts to obtain the complaint sample from the complainant. If insufficient attempts were made, identify the root cause(s) for not adequately pursuing their return.\no For all complaint investigations found by the retrospective review to be deficient, to have an inconclusive root cause, or to have no root cause identified, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, OOS history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation and any identified CAPA (e.g., manufacturing operation improvements).\no Identify any patterns or trends across complaints that may indicate systemic manufacturing, quality control, supplier qualification, or design issues requiring corrective action.\no Based upon this independent review, provide a comprehensive assessment of your overall complaint handling program that identifies any deficiencies and corresponding CAPA.\nA comprehensive review and remediation plan for your OOS-result investigation systems. The CAPA should include but not be limited to addressing the following:\no Quality unit oversight of laboratory investigations\no Identification of adverse laboratory control trends\no Resolution of causes of laboratory variation\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\no Adequate scoping of each investigation and its CAPA\no Revised OOS investigation procedures with these and other remediations\nProvide a comprehensive, independent review of your process capability and quality performance, including:\no Comprehensive identification of all defects encountered at each manufacturing process stage.\no Classification of each identified defect by type, frequency (i.e., average, range), severity, and root cause(s).\no Analysis of multi-year, longitudinal batch-to-batch trending data for each defect.\no Actual in-process and finished product yield data for each batch.\no Process capability index calculations for all critical manufacturing steps.\no A thorough independent assessment of both sporadic (i.e., unexpected spikes) and average variability observed based upon detailed review of above items. Provide analytical findings, associated operational weaknesses and root causes, and potential remediation options.\nYour commitment to implement CAPA based on the above process performance analysis and to begin conducting annual capability analysis with quality oversight across all product lines.\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\nYour firm lacked appropriate spore population verification on in-house prepared biological indicators (BIs) used in your (b)(4) sterilization (b)(4) process. You used these BIs for verifying sterilization effectiveness and as a batch release specification for (b)(4) drug products.\nYou validated your method for preparing BIs for your (b)(4) process in 2015 and included a target specification for (b)(4) spores of (b)(4) colony forming units (CFU). However, you have failed to perform quantitative verification of the spore population for these BIs since the initial validation. Instead, your firm has relied on a combination of vendor certificates for the initial spore count, theoretical calculations, and qualitative (growth\u002Fno growth) testing after (b)(4) with the final prepared BIs to evaluate sterilization effectiveness. Your procedure for preparing BIs states that population verification is not required because the preparation method was validated. However, validation of a preparation method does not eliminate the need for ongoing verification.\nIn your response, you state that you have subsequently performed verification studies on recent BI preparations, and you commit to implementing ongoing verification. You also state that there is no impact to finished products because your (b)(4) parameters are set to ensure the reproducibility of the (b)(4) process.\nYour response is inadequate because you did not assess the impact of the lack of quantitative verification of your BIs. Your assertion of (b)(4) process reproducibility assumes the BIs consistently contained adequate spore populations, which you have not demonstrated.\nWithout quantitative verification, you cannot determine whether “no growth” results after (b)(4) are due to an effective sterilization cycle or are because the BIs are lacking sufficient viable spore population.\nIn response to this letter, provide:\nA list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nFor any (b)(4) products that are not terminally sterilized by your company (or its contract facilities), explain whether you distribute these unsterilized products with the expectation that your customers will ultimately perform terminal sterilization of these batches.\nA comprehensive plan and timeline to transition all (b)(4) drug products to terminal sterilization. If your firm does not intend to transition all (b)(4) drug products to terminal sterilization, provide a detailed rationale justifying your scientific and public health basis. Also include a risk assessment that addresses your history of sterility-related quality issues.\nA comprehensive process description for all (b)(4) products your firm distributes. When describing each of the process options that your firm can use, detail whether the (b)(4) finished product is sterilized. For any process option that does not involve (b)(4) (including (b)(4)) prior to sterilization, comprehensively describe the (b)(4) steps that occur following the interim sterilization step. Also explain whether (b)(4) are sterilized, and if not, what your microbial bioburden specifications are for these parts and under what cleanroom conditions (b)(4) occurs.\n3. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment; and failed to perform operations within specifically defined areas of adequate size; and failed to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups (21 CFR 211.67(b) and 21 CFR 211.42(c)).\nDuring our inspection, we observed inadequate cleaning and inadequate contamination control throughout your manufacturing facility where sterile drug products are assembled and packaged.\nFor example, our investigators found (b)(4) and (b)(4) inside your (b)(4) chambers which sterilize your drug product ampoules. During the inspection, your firm confirmed that the chamber cleaning procedure involved (b)(4) the (b)(4) chambers (b)(4) to remove (b)(4). However, we noted multiple instances of your operators’ failure to appropriately document (b)(4) during a period when multiple U.S. batches were being sterilized. Additionally, you did not test the (b)(4) used in your (b)(4) process for chemical or microbiological specifications. Unsuitable (b)(4) quality could introduce (b)(4), (b)(4), and bioburden – further compromising chamber cleanliness and sterilization efficacy.\nFDA investigators observed (b)(4) residue on air vents, walls, and equipment surfaces in your main production area, packaging lines, ampoule rinsing room, and equipment washroom, despite cleaning logs documenting these areas had been cleaned. FDA investigators also observed broken (b)(4) on (b)(4) with sterilized ampoules next to assembly lines where these ampoules are (b)(4).\nYour contamination control practices were also inadequate. FDA investigators observed personnel wearing face masks improperly in violation of your gowning procedures. Your quality notification QN 201162939 documented a bioburden excursion in non-sterile (b)(4) product showing (b)(4) CFU with Streptococcus pneumoniae identified, a significant opportunistic pathogen commonly found in the nose and throat.\nMultiple environmental monitoring (EM) excursions also occurred in your filling areas. These contamination control failures are particularly worrisome if your (b)(4) do not ultimately undergo terminal sterilization on the (b)(4), including the (b)(4). When terminal sterilization is not applied to the finished product, robust aseptic processing control becomes critical to ensuring product sterility.\nNotably, robust manufacturing design and control to prevent contamination also applies if (b)(4) are not intended to be sterile, when appropriate based on their indication. Such products must be free of microbes that may be objectionable in view of their intended use.\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nYour response states that you engaged an independent third-party expert to review and redesign your cleaning validation program and committed to implementing cleaning validation for equipment and product-contact surfaces. You identified the (b)(4) residue as (b)(4) used in certain (b)(4) and stated you evaluated chromatography data to confirm the absence of cross-contamination to other products. You conducted a risk assessment of your cleaning program and concluded that existing process controls at various manufacturing stages would detect and reject products containing residues, contaminants, or microorganisms beyond acceptable limits.\nYour response is inadequate. Your commitment to implement cleaning validation does not address products currently in distribution manufactured under the conditions documented during the inspection. Your conclusion that existing controls would robustly detect contamination is contradicted by the nature of the customer complaints received by your firm, particularly given the extent of contamination, debris, gowning violations, and EM excursions documented during the inspection. Additionally, your identification of the (b)(4) residue and review of chromatography data do not address why your cleaning procedures failed to prevent its accumulation.\nInadequate removal of debris and residues from manufacturing equipment during cleaning can lead to contamination of drug products subsequently manufactured on the equipment. In addition, inadequate operational controls to prevent contamination can jeopardize patient safety by potentially compromising the sterility of products designed to (b)(4).\nIn response to this letter, provide:\nA comprehensive, independent assessment of your bioburden control program for non-sterile components and finished drug products. This assessment should include:\no Bioburden testing and trending data for each lot of incoming (b)(4) received over the last three years, including total aerobic microbial count (TAMC), total yeast and mold count (TYMC), as well as all identification testing performed and organisms detected.\no Bioburden and sterility testing data for all finished product batches manufactured over the last three years, including all data obtained when testing in-process and finished product batch units, as well as complete microbial identification of all organisms detected.\no A comprehensive review by the independent third party of all microbiological test results (TAMC, TYMC, sterility tests, and organism identifications) for the last three years, including any OOS results that were subsequently invalidated. For any invalidated OOS results, assess the adequacy of the scientific justification and evidence supporting the invalidation decision.\no An independent third-party review of your laboratory’s microbiological methods. The review should determine whether the methods are scientifically sound and capable of reliably detecting, quantifying, and identifying any bioburden present in incoming (b)(4) and finished drug products.\no A summary report of all bioburden and sterility data collected from the above assessments, including trend analysis, identification of any patterns or excursions, and corresponding CAPA to address any deficiencies identified.\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\nA CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program including enhancements to cleaning effectiveness, improved ongoing verification of proper cleaning execution for all products and equipment, and all other needed remediations.\nAppropriate improvements to your cleaning validation program with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\no drugs with higher toxicities\no drugs with higher drug potencies\no drugs of lower solubility in their cleaning solvents\no drugs with characteristics that make them difficult to clean\no swabbing locations for areas that are most difficult to clean\no maximum hold times before cleaning\nDescribe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nAn independent, comprehensive review of your EM program to ensure vigilant, timely detection and response to potential product contamination hazards in your manufacturing environment. This assessment should include, but not be limited to:\no establishing appropriate limits\no sampling methods\no sampling locations and frequencies\no trend analysis\no appropriate investigation of deviations and adverse trends\no and a comprehensive CAPA plan based on the findings of the assessment\nA procedure for your (b)(4) system monitoring that specifies routine microbial and chemical testing of (b)(4) to ensure its acceptability for use in each batch of drug products produced by your firm, as well as its use in sterilization processes.\nThe current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) system.\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures your (b)(4) system consistently produces (b)(4) meeting appropriate chemical and microbial limits for use in (b)(4) process.\nAssurance of Sterility – Terminal Sterilization\nIt should be noted that although the sterility test is a critical final quality control for (b)(4) finished products that purport to be sterile, it cannot be solely relied upon as justification to release each drug product batch. The sterility test is only the last in a series of design and control provisions intended to protect the consumer from distribution of an unsafe batch. Sample sizes for sterility testing are typically small compared to the total number of units in a batch and may not detect sporadic non-sterility. For example, a failure to consistently execute a terminal sterilization cycle of the finished product within its validated state, or a sporadic container-closure issue, may go undetected for substantial periods if your firm places too much reliance on the final quality control test for sterility to identify a sterility assurance problem. It is also essential to note that any positive sterility test result represents a serious CGMP issue that requires a comprehensive investigation into the cause and extent of the problem, and prompt review of the validated status of your terminal sterilization process.\nRepeat Observations at Facility\nIn previous inspections occurring in 2023 and 2016, FDA has repeatedly cited similar CGMP observations. In 2016, FDA cited your firm for failure to perform adequate investigations of product failures. In 2023, FDA cited your firm for failure to ensure adequate laboratory controls and failure to maintain facilities in a good state of repair. The current inspection reveals these deficiencies have persisted or recurred, demonstrating that executive management oversight and control over the manufacture of drugs is inadequate.\nQuality Unit Authority\nSignificant findings in this letter indicate that your quality unit is not fully exercising its authority and\u002For responsibilities. Your firm must provide the quality unit with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\nFor guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: Q8(R2) Pharmaceutical Development at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload, Q9(R1) Quality Risk Management at\nhttps:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167721\u002Fdownload, and Q10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004932373 and ATTN: Bryce Hammer.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","CareFusion 213, LLC","carefusion-213-llc-722729-04302026","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcarefusion-213-llc-722729-04302026","2026-10-26T08:08:11.324677+00:00","Warning Letter","Issued","2026-05-05","722729","Drugs","Mr. Thomas E. Polen, Jr.","2026-08-19T04:43:37.595+00:00","Via Electronic Mail - Return Receipt Requested","320-26-72","2026-04-30",{"id":33,"raw":34,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":19,"letter_url":46,"updated_at":47,"action_type":22,"case_status":23,"posted_date":48,"marcs_cms_no":49,"product_type":26,"closeout_date":19,"issuing_office":50,"recipient_name":51,"body_fetched_at":52,"delivery_method":53,"recipient_title":19,"reference_number":19,"action_taken_date":54,"medical_device_id":19,"response_letter_date":19},2059,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2023-06-13T13:20:00Z\">06\u002F13\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-05-22T04:00:00Z\">05\u002F22\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcarolina-infusion-659408-05222023\">Carolina Infusion\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations II ","Compounding Pharmacy\u002FAdulterated Drug Products ","Compounding Pharmacy\u002FAdulterated Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Melissa Etheridge\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Carolina Infusion\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>95 Bees Creek Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ridgeland\u003C\u002Fspan>, \u003Cspan>SC\u003C\u002Fspan> \u003Cspan>29936-7540\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations II \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 22, 2023\u003C\u002Fp>\n\n\u003Cp>Case # 659408\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Etheridge:\u003C\u002Fp>\n\n\u003Cp>From July 18, 2022 to August 12, 2022, a U.S. Food and Drug Administration (FDA) investigator inspected your facility, Carolina Infusion, located at 95 Bees Creek Road, Ridgeland, SC 29936. During the inspection, the investigator noted that drug products you produced failed to meet the conditions of section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353a] for exemption from certain provisions of the FDCA. In addition, the investigator noted serious deficiencies in your practices for producing non-sterile drug products and drug products intended or expected to be sterile, which put patients at risk.\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your firm on August 12, 2022. FDA acknowledges receipt of your facility’s response, dated September 1, 2022. FDA acknowledges that on August 26, 2022, your firm initiated a voluntary recall of all products intended to be sterile that were within expiry due to a lack of sterility assurance. We also acknowledge that you have ceased production of “intrathecal administered medications at this time.” Based on this inspection, it appears that you produced drug products that violate the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. Compounded Drug Products Under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Receipt of valid prescriptions for individually identified patients is one of the conditions for the exemptions under section 503A.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. Failure to Meet the Conditions of Section 503A\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection, the FDA investigator noted that drug products produced by your firm failed to meet the conditions of section 503A. For example, the investigator noted that your firm did not receive valid prescriptions for individually identified patients for a portion of the drug products you produced, including Tri-Mix 30\u002F2\u002F20 Injectable, Lidocaine\u002FTetracaine\u002FPhenylephrine 21%\u002F7%\u002F2% Ointment, and Lidocaine\u002FTetracaine 23%\u002F7% Plasticized.\u003C\u002Fp>\n\n\u003Cp>Therefore, you compounded drug products that do not meet the conditions of section 503A and are not eligible for the exemptions in that section, including the FDA approval requirement of section 505 of the FDCA, the requirement under section 502(f)(1) of the FDCA that labeling bear adequate directions for use, and the requirement of compliance with CGMP under section 501(a)(2)(B) of the FDCA. In the remainder of this letter, we refer to your drug products that do not qualify for exemptions under section 503A as the “ineligible drug products.”\u003C\u002Fp>\n\n\u003Cp>Specific violations are described below\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The FDA investigator noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed the following:\u003C\u002Fp>\n\n\u003Cp>1. Your firm produced drug products with materials that had not been verified to assure that they did not contribute endotoxin contamination that may be objectionable given the product’s intended use.\u003C\u002Fp>\n\n\u003Cp>2. Your facility design allowed the influx of poor-quality air into a higher classified area.\u003C\u002Fp>\n\n\u003Cp>3. Your firm used non-pharmaceutical grade components in the formulation of non-sterile drug products.\u003C\u002Fp>\n\n\u003Cp>4. Your media fills were not performed under the most challenging or stressful conditions. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\u003C\u002Fp>\n\n\u003Cp>5. Your ISO-5 classified areas were not certified under dynamic conditions.\u003C\u002Fp>\n\n\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a), the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You do not have any FDA-approved applications on file for the ineligible drug products that you compounded.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. § 331(d)], a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The ineligible drug products you compounded are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Accordingly, these ineligible drug products are misbranded under section 502(f)(1) of the FDCA. The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. It is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s responses to the Form FDA 483. We acknowledge your recall of drug products intended to be sterile within expiry due to a lack of sterility assurance on August 26, 2022. In addition, we acknowledge that your firm ceased all sterile drug production on August 24th, 2022, and that your firm resumed sterile drug production on October 14, 2022, except for intrathecal drug products.\u003C\u002Fp>\n\n\u003Cp>Regarding your responses related to the insanitary conditions, some of your corrective actions appear adequate; however, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation:\u003C\u002Fp>\n\n\u003Cp>1. You stated in your response that you revised the endotoxin testing SOP 9.170, Version Number 2.0, \u003Cem>Serial Dilution for Intrathecal Endotoxin Testing\u003C\u002Fem> and that your firm “does not pool different finished compounded intrathecal compounded drug products into one unit.” However, this statement or information of not pooling different intrathecal finished drug products during endotoxin testing is not included in the revised SOP provided. In addition, you did not provide any supporting training documentation showing your staff were trained on this new procedure.\u003C\u002Fp>\n\n\u003Cp>2. You stated in your response that you “will be using \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the formulation of these non-sterile compounds.” This would be effective September 1, 2022. However, you did not provide any supporting documentation such as invoices showing the proof of purchase or training documentation for staff pertaining to the use of&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> in non-sterile drug production.\u003C\u002Fp>\n\n\u003Cp>3. You stated in your response that your certification vendor, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, acknowledged that there were errors associated with the differential pressure reporting in the initial \u003Cstrong>(b)(4)\u003C\u002Fstrong> report (Report #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated 2\u002F23\u002F2022) submitted to the firm and the report was changed. However, you did not provide the revised report for review, and therefore, we cannot evaluate the changes made to the initial \u003Cstrong>(b)(4)\u003C\u002Fstrong> report or its adequacy.\u003C\u002Fp>\n\n\u003Cp>4. You stated that “no growth was observed after swabbing and \u003Cstrong>(b)(4)\u003C\u002Fstrong> plating” post cleaning of the anteroom with “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and cleaning of the sink within the room with \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>upon learning of the actionable growth observed in the February 2022 environmental sampling performed by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you did not provide any supporting evidence such as cleaning logs or subsequent environmental sampling data for evaluation. In addition, your firm’s recent \u003Cstrong>(b)(4)\u003C\u002Fstrong> report performed on August 30, 2022, indicates that “microbiological analysis (viable count)” was performed. However, the report provided as part of the response did not include the results of the viable count from this sampling date.\u003C\u002Fp>\n\n\u003Cp>You did not address certain observations related to insanitary conditions, for example:\u003C\u002Fp>\n\n\u003Cp>1. Your firm did not address the concerns associated with the lack of endotoxin control during the production process and then release of intrathecal drug products when the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment is not available for testing. Without endotoxin controls (such as endotoxin data on CoAs for bulk drug substances and other components, finished product endotoxin testing, etc.), there are no assurances that intrathecal drug products are safe for their intended use.\u003C\u002Fp>\n\n\u003Cp>2. The new endotoxin results tested on 08\u002F17\u002F2022 provided by your firm did not include or address the finished drug products for intrathecal use that are combination of two or more APIs which your firm also produces.\u003C\u002Fp>\n\n\u003Cp>Regarding your responses related to the insanitary conditions, the following corrective actions appear deficient:\u003C\u002Fp>\n\n\u003Cp>1. You have not addressed the lack of established endotoxin limit for your sterile intrathecal finished drug products. The acceptability of the new endotoxin results tested on 08\u002F17\u002F2022 submitted for evaluation cannot be fully determined because no endotoxin limit or calculation of the endotoxin limit for the intrathecal finished drug products associated with these samples were provided for evaluation.\u003C\u002Fp>\n\n\u003Cp>2. You stated in your response that the revised endotoxin test procedure includes the use of single use containers. However, although the revised SOP # 9.170 Version Number 2.0,&nbsp;\u003Cem>Serial Dilution for Intrathecal Endotoxin Testing\u003C\u002Fem>, mentions the use of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>tubes within the document, it does not indicate that the tubes are single use containers. In addition, you did not provide any supporting training documentation showing your staff were trained on this new procedure, and know how to correctly operate the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>equipment, or interpret the endotoxin report from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment.\u003C\u002Fp>\n\n\u003Cp>3. Your response to inadequate pressure differentials in the sterile compounding cleanroom conveyed that the only way the differential pressure “could possibly go below \u003Cstrong>(b)(4)\u003C\u002Fstrong>” is “if the door had not been shut and the door cracked open.” If this is accurate, then your firm’s monitoring system for differential pressures failed to adequately detect a drop in differential pressure and provide real time notification, therefore, putting the cleanroom (certified as ISO 6 where ISO 5 hoods are located, and sterile products including intrathecals are produced) at risk for potential influx of poor-quality air to enter the cleanroom undetected.\u003C\u002Fp>\n\n\u003Cp>4. You stated in your response that your access hallway “is not neutral, it is positive pressure with an ISO 6 classification.” However, the supporting evidence provided by your firm contradicts this statement because the hallway certification report dated June 21, 2022, has the hallway as “Work Area Pressure: Neutral, Neutral to All Rooms.” Your response also stated that the hallway is classified as an ISO 6 and “since the rooms are also ISO 6, upon opening the door to any of the rooms, there is neutral pressure because all rooms and hallway are ISO-6. Therefore, no contaminants can come in or out of the room.” You provided no evidence, such as testing data or reports, to support that the facility design would prevent contamination, specifically, in the sterile compounding cleanroom where ISO 5 hoods are located, and sterile production occurs. In addition, your response further states “anti-room is a positive pressure room, and the hallway is not neutral” but you provided no evidence, such as a certification report, to prove this claim.\u003C\u002Fp>\n\n\u003Cp>5. Review of your prescription batch records show that you produce more complex preparations during sterile drug production than what your firm demonstrated using the media fill kit from&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example:\u003C\u002Fp>\n\n\u003Cp>&nbsp; a. Your firm performs more complex filling procedure such as producing and filling directly into patient specific syringes as the final container closure and filling a higher number of units than what was demonstrated using the media fill kit from \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>&nbsp; b. Your firm also performs more complex compounding procedure including the use of nonsterile stock solutions with 90 days and 180 days beyond use date (BUD). The hold time for the non-sterile stock solution in this more complex procedure was not considered in your firm’s current media fill procedure.\u003C\u002Fp>\n\n\u003Cp>6. The certification reports for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> ISO 5 hoods did not indicate that they were performed under dynamic conditions which is different from the certification reports for your “compounding room \u003Cstrong>(b)(4)\u003C\u002Fstrong> that stated, “Tested Under Dynamic Cond.” In addition, you state that “we do not load the hood with items not intended for that specific prescription,”. It is unclear how you define “dynamic condition” and under what dynamic conditions the hoods are certified. Your SOP 3.010 Rev. 1.0, \u003Cem>Sterile Compounding Area Requirements\u003C\u002Fem>, does not indicate certification of your ISO 5 hoods need to be performed under dynamic conditions.\u003C\u002Fp>\n\n\u003Cp>For more information on compounding, please see FDA's website, at https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FPharmacyCompounding\u002Fdefault.htm\u003C\u002Fp>\n\n\u003Cp>Please be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A, including the condition on receipt of a prescription for an identified individual patient prior to compounding and distributing drug products.\u003C\u002Fp>\n\n\u003Cp>In addition, regarding issues related to the conditions of section 503A of the FDCA, your corrective actions appear adequate. You state that your “pharmacy has ceased and will no longer produce products for physician office stock.”\u003C\u002Fp>\n\n\u003Cp>Should you continue to compound and distribute drug products that do not meet the conditions of section 503A, the compounding and distribution of such drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the drug CGMP regulations. Before doing so, you must comply with the requirements of section 505 and 502(f)(1) and fully implement corrections that meet the minimum requirements of the CGMP regulations.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b)].\u003C\u002Fp>\n\n\u003Cp>FDA strongly recommends, especially if you decide to resume production of sterile intrathecal drug products, your management undertake a comprehensive assessment of operations, including but not limited to establishing product endotoxin limit, facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise including intrathecal and endotoxin testing should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>E. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. In addition, if you intend to resume production of sterile drugs for intrathecal administration in the future, please notify this office in writing. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time in which you will do so.\u003C\u002Fp>\n\n\u003Cp>You written notification should refer to the Warning Letter Number above (659408). Please electronically submit your reply on company letterhead to Mark W. Rivero, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov. In addition, please submit a signed copy of your response to mark.rivero@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Ronda Loyd-Jones, Director, Compliance Branch, by email at ronda.loyd-jones@fda.hhs.gov or by phone at (214) 253 - 5336, or Mr. Mark Rivero by e-mail or by phone at (954) 759 - 7718.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Monica R. Maxwell\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations,\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\u003Cp>_____________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The specific products made by your firm are drugs within the meaning of section 201(g) of the Act, [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) [21 U.S.C. 321(p)] of the FDCA because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Your ineligible drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> In this letter we do not address whether your proposed corrective actions would resolve the CGMP violations noted above.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMelissa Etheridge\n\nRecipient Title\n\nOwner\n\nCarolina Infusion\n\n95 Bees Creek Road\n\nRidgeland, SC 29936-7540\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations II\n\nUnited States\n\nMay 22, 2023\n\nCase # 659408\n\nWARNING LETTER\n\nDear Ms. Etheridge:\n\nFrom July 18, 2022 to August 12, 2022, a U.S. Food and Drug Administration (FDA) investigator inspected your facility, Carolina Infusion, located at 95 Bees Creek Road, Ridgeland, SC 29936. During the inspection, the investigator noted that drug products you produced failed to meet the conditions of section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353a] for exemption from certain provisions of the FDCA. In addition, the investigator noted serious deficiencies in your practices for producing non-sterile drug products and drug products intended or expected to be sterile, which put patients at risk.\n\nFDA issued a Form FDA 483 to your firm on August 12, 2022. FDA acknowledges receipt of your facility’s response, dated September 1, 2022. FDA acknowledges that on August 26, 2022, your firm initiated a voluntary recall of all products intended to be sterile that were within expiry due to a lack of sterility assurance. We also acknowledge that you have ceased production of “intrathecal administered medications at this time.” Based on this inspection, it appears that you produced drug products that violate the FDCA.\n\nA. Compounded Drug Products Under the FDCA\n\nSection 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].1 Receipt of valid prescriptions for individually identified patients is one of the conditions for the exemptions under section 503A.\n\nB. Failure to Meet the Conditions of Section 503A\n\nDuring the inspection, the FDA investigator noted that drug products produced by your firm failed to meet the conditions of section 503A. For example, the investigator noted that your firm did not receive valid prescriptions for individually identified patients for a portion of the drug products you produced, including Tri-Mix 30\u002F2\u002F20 Injectable, Lidocaine\u002FTetracaine\u002FPhenylephrine 21%\u002F7%\u002F2% Ointment, and Lidocaine\u002FTetracaine 23%\u002F7% Plasticized.\n\nTherefore, you compounded drug products that do not meet the conditions of section 503A and are not eligible for the exemptions in that section, including the FDA approval requirement of section 505 of the FDCA, the requirement under section 502(f)(1) of the FDCA that labeling bear adequate directions for use, and the requirement of compliance with CGMP under section 501(a)(2)(B) of the FDCA. In the remainder of this letter, we refer to your drug products that do not qualify for exemptions under section 503A as the “ineligible drug products.”\n\nSpecific violations are described below\n\nC. Violations of the FDCA\n\nAdulterated Drug Products\n\nThe FDA investigator noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed the following:\n\n1. Your firm produced drug products with materials that had not been verified to assure that they did not contribute endotoxin contamination that may be objectionable given the product’s intended use.\n\n2. Your facility design allowed the influx of poor-quality air into a higher classified area.\n\n3. Your firm used non-pharmaceutical grade components in the formulation of non-sterile drug products.\n\n4. Your media fills were not performed under the most challenging or stressful conditions. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\n\n5. Your ISO-5 classified areas were not certified under dynamic conditions.\n\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a), the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\n\nUnapproved New Drug Products\n\nYou do not have any FDA-approved applications on file for the ineligible drug products that you compounded.2 Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. § 331(d)], a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\n\nMisbranded Drug Products\n\nThe ineligible drug products you compounded are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses.3 Accordingly, these ineligible drug products are misbranded under section 502(f)(1) of the FDCA. The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. It is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\n\nD. Corrective Actions\n\nWe have reviewed your firm’s responses to the Form FDA 483. We acknowledge your recall of drug products intended to be sterile within expiry due to a lack of sterility assurance on August 26, 2022. In addition, we acknowledge that your firm ceased all sterile drug production on August 24th, 2022, and that your firm resumed sterile drug production on October 14, 2022, except for intrathecal drug products.\n\nRegarding your responses related to the insanitary conditions, some of your corrective actions appear adequate; however, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation:\n\n1. You stated in your response that you revised the endotoxin testing SOP 9.170, Version Number 2.0, Serial Dilution for Intrathecal Endotoxin Testing and that your firm “does not pool different finished compounded intrathecal compounded drug products into one unit.” However, this statement or information of not pooling different intrathecal finished drug products during endotoxin testing is not included in the revised SOP provided. In addition, you did not provide any supporting training documentation showing your staff were trained on this new procedure.\n\n2. You stated in your response that you “will be using (b)(4) in the formulation of these non-sterile compounds.” This would be effective September 1, 2022. However, you did not provide any supporting documentation such as invoices showing the proof of purchase or training documentation for staff pertaining to the use of (b)(4) in non-sterile drug production.\n\n3. You stated in your response that your certification vendor, (b)(4), acknowledged that there were errors associated with the differential pressure reporting in the initial (b)(4) report (Report #(b)(4), dated 2\u002F23\u002F2022) submitted to the firm and the report was changed. However, you did not provide the revised report for review, and therefore, we cannot evaluate the changes made to the initial (b)(4) report or its adequacy.\n\n4. You stated that “no growth was observed after swabbing and (b)(4) plating” post cleaning of the anteroom with “(b)(4)” and cleaning of the sink within the room with (b)(4) upon learning of the actionable growth observed in the February 2022 environmental sampling performed by (b)(4). However, you did not provide any supporting evidence such as cleaning logs or subsequent environmental sampling data for evaluation. In addition, your firm’s recent (b)(4) report performed on August 30, 2022, indicates that “microbiological analysis (viable count)” was performed. However, the report provided as part of the response did not include the results of the viable count from this sampling date.\n\nYou did not address certain observations related to insanitary conditions, for example:\n\n1. Your firm did not address the concerns associated with the lack of endotoxin control during the production process and then release of intrathecal drug products when the (b)(4) equipment is not available for testing. Without endotoxin controls (such as endotoxin data on CoAs for bulk drug substances and other components, finished product endotoxin testing, etc.), there are no assurances that intrathecal drug products are safe for their intended use.\n\n2. The new endotoxin results tested on 08\u002F17\u002F2022 provided by your firm did not include or address the finished drug products for intrathecal use that are combination of two or more APIs which your firm also produces.\n\nRegarding your responses related to the insanitary conditions, the following corrective actions appear deficient:\n\n1. You have not addressed the lack of established endotoxin limit for your sterile intrathecal finished drug products. The acceptability of the new endotoxin results tested on 08\u002F17\u002F2022 submitted for evaluation cannot be fully determined because no endotoxin limit or calculation of the endotoxin limit for the intrathecal finished drug products associated with these samples were provided for evaluation.\n\n2. You stated in your response that the revised endotoxin test procedure includes the use of single use containers. However, although the revised SOP # 9.170 Version Number 2.0, Serial Dilution for Intrathecal Endotoxin Testing, mentions the use of (b)(4) tubes within the document, it does not indicate that the tubes are single use containers. In addition, you did not provide any supporting training documentation showing your staff were trained on this new procedure, and know how to correctly operate the (b)(4) equipment, or interpret the endotoxin report from the (b)(4) equipment.\n\n3. Your response to inadequate pressure differentials in the sterile compounding cleanroom conveyed that the only way the differential pressure “could possibly go below (b)(4)” is “if the door had not been shut and the door cracked open.” If this is accurate, then your firm’s monitoring system for differential pressures failed to adequately detect a drop in differential pressure and provide real time notification, therefore, putting the cleanroom (certified as ISO 6 where ISO 5 hoods are located, and sterile products including intrathecals are produced) at risk for potential influx of poor-quality air to enter the cleanroom undetected.\n\n4. You stated in your response that your access hallway “is not neutral, it is positive pressure with an ISO 6 classification.” However, the supporting evidence provided by your firm contradicts this statement because the hallway certification report dated June 21, 2022, has the hallway as “Work Area Pressure: Neutral, Neutral to All Rooms.” Your response also stated that the hallway is classified as an ISO 6 and “since the rooms are also ISO 6, upon opening the door to any of the rooms, there is neutral pressure because all rooms and hallway are ISO-6. Therefore, no contaminants can come in or out of the room.” You provided no evidence, such as testing data or reports, to support that the facility design would prevent contamination, specifically, in the sterile compounding cleanroom where ISO 5 hoods are located, and sterile production occurs. In addition, your response further states “anti-room is a positive pressure room, and the hallway is not neutral” but you provided no evidence, such as a certification report, to prove this claim.\n\n5. Review of your prescription batch records show that you produce more complex preparations during sterile drug production than what your firm demonstrated using the media fill kit from (b)(4). For example:\n\na. Your firm performs more complex filling procedure such as producing and filling directly into patient specific syringes as the final container closure and filling a higher number of units than what was demonstrated using the media fill kit from (b)(4).\n\nb. Your firm also performs more complex compounding procedure including the use of nonsterile stock solutions with 90 days and 180 days beyond use date (BUD). The hold time for the non-sterile stock solution in this more complex procedure was not considered in your firm’s current media fill procedure.\n\n6. The certification reports for your (b)(4) ISO 5 hoods did not indicate that they were performed under dynamic conditions which is different from the certification reports for your “compounding room (b)(4) that stated, “Tested Under Dynamic Cond.” In addition, you state that “we do not load the hood with items not intended for that specific prescription,”. It is unclear how you define “dynamic condition” and under what dynamic conditions the hoods are certified. Your SOP 3.010 Rev. 1.0, Sterile Compounding Area Requirements, does not indicate certification of your ISO 5 hoods need to be performed under dynamic conditions.\n\nFor more information on compounding, please see FDA's website, at https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FPharmacyCompounding\u002Fdefault.htm\n\nPlease be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A, including the condition on receipt of a prescription for an identified individual patient prior to compounding and distributing drug products.\n\nIn addition, regarding issues related to the conditions of section 503A of the FDCA, your corrective actions appear adequate. You state that your “pharmacy has ceased and will no longer produce products for physician office stock.”\n\nShould you continue to compound and distribute drug products that do not meet the conditions of section 503A, the compounding and distribution of such drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the drug CGMP regulations. Before doing so, you must comply with the requirements of section 505 and 502(f)(1) and fully implement corrections that meet the minimum requirements of the CGMP regulations.4\n\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b)].\n\nFDA strongly recommends, especially if you decide to resume production of sterile intrathecal drug products, your management undertake a comprehensive assessment of operations, including but not limited to establishing product endotoxin limit, facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise including intrathecal and endotoxin testing should assist you in conducting this comprehensive evaluation.\n\nE. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. In addition, if you intend to resume production of sterile drugs for intrathecal administration in the future, please notify this office in writing. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time in which you will do so.\n\nYou written notification should refer to the Warning Letter Number above (659408). Please electronically submit your reply on company letterhead to Mark W. Rivero, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov. In addition, please submit a signed copy of your response to mark.rivero@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, please contact Ronda Loyd-Jones, Director, Compliance Branch, by email at ronda.loyd-jones@fda.hhs.gov or by phone at (214) 253 - 5336, or Mr. Mark Rivero by e-mail or by phone at (954) 759 - 7718.\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations,\n\nDivision II\n\n_____________________________________\n\n1 We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\n\n2 The specific products made by your firm are drugs within the meaning of section 201(g) of the Act, [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) [21 U.S.C. 321(p)] of the FDCA because they are not generally recognized as safe and effective for their labeled uses.\n\n3 Your ineligible drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\n\n4 In this letter we do not address whether your proposed corrective actions would resolve the CGMP violations noted above.","Carolina Infusion","carolina-infusion-659408-05222023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcarolina-infusion-659408-05222023","2026-10-26T08:08:11.619829+00:00","2023-06-13","659408","Division of Pharmaceutical Quality Operations II","Melissa Etheridge","2026-08-20T01:03:04.884+00:00","Via Email","2023-05-22",{"id":56,"raw":57,"subject":62,"body_html":63,"body_text":64,"firm_name":65,"letter_id":66,"created_at":67,"fei_number":19,"letter_url":68,"updated_at":69,"action_type":22,"case_status":23,"posted_date":70,"marcs_cms_no":71,"product_type":72,"closeout_date":19,"issuing_office":61,"recipient_name":73,"body_fetched_at":74,"delivery_method":53,"recipient_title":19,"reference_number":19,"action_taken_date":75,"medical_device_id":19,"response_letter_date":19},1134,[58,59,60,61,62,13,13,13],"\u003Ctime datetime=\"2024-12-17T14:20:00Z\">12\u002F17\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-22T05:00:00Z\">11\u002F22\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbecton-dickinson-and-companycarefusion-303-inc-691601-11222024\">Becton, Dickinson, and Company\u002FCareFusion 303, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Thomas E. Polen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Becton, Dickinson, and Company\u002FCareFusion 303, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1 Becton Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Franklin Lakes\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07417\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>11\u002F22\u002F2024\u003C\u002Fp>\u003Cp>Dear Mr. Polen:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in San Diego, California on May 6, 2024 through May 22, 2024, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm manufactures Pyxis Medication Management System medical devices including, but not limited to, Pyxis MedStation ES, Pyxis ES Anesthesia, and Pyxis MedBank (hereafter also referred to as Pyxis) Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality System Regulation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Vipul Sheth, VP of Quality, MMS dated June 13, 2024 and additional responses dated July 31, 2024 and September 20, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and implement procedures for corrective and preventive actions as required by 21 CFR 820.100(a).\u003C\u002Fp>\u003Cp>For example, you were found to have 544 open tickets for software defects of which 111 were categorized as Catastrophic or Severe patient harm. Four (4) were noted to have\u003Cbr>cybersecurity vulnerabilities. Of 256 open tickets for server software issues, 55 for thermal effects were categorized as Catastrophic or Severe. Your CAPA # 8438925 was not found to be complete.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time.\u003C\u002Fp>\u003Cp>You provided an Issue and Defect Tracking procedure and stated that closure of “Tickets” will be tracked in a risk-prioritized manner by June 30, 2025 and conduct training. You state that you established a quality metric that monitors the timely closure of “Defects” and presented to the FY2024 Q3 Quarterly Management Review meeting to determine the definition of metric. You have not provided the results of the management review. You also stated you will enhance your \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You have not provided evidence of implementation of these corrective actions.\u003C\u002Fp>\u003Cp>2. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>For example, for 8 complaints [04168007, 04167379, 04170044, 04178943, 04179552, 041686160, 04208805, and 04211537] during the December 2023 to January 2024 time period, for issues with the Pyxis \u003Cstrong>(b)(4)\u003C\u002Fstrong> server, e.g., servers offline at three hospitals and required shutdown, none of the complaints were evaluated for MDR reporting. You stated that MDR reportability is not done for \u003Cstrong>(b)(4)\u003C\u002Fstrong> server complaints because the server is not a medical device, and that the server is not part of the Pyxis system. Your firm provided evidence of a regulatory assessment as \u003Cstrong>(b)(4)\u003C\u002Fstrong> Server Baseline Regulatory Assessment, DIR #10000428322.\u003C\u002Fp>\u003Cp>Your firm uses the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system to document complaints and has a Complaint Handling Procedure. You also have a Complaint Investigation procedure, but you stated you only perform investigations for MDR reportable complaints. In a review of two spreadsheets, Case Notes for Reportable was noted as N\u002FA. Your firm was found to have approximately 92, 083 complaints for delay in delivery of medications due to freezing, shut down, or malfunction including complaints and 70 complaints for wrong medications dispensed, without evidence of investigation. Also, eight (8) complaints reported potential electrical safety issues with the Pyxis MedBank Dispensing Cabinet, however none were investigated.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time.\u003C\u002Fp>\u003Cp>You stated that complaint investigations were not comprehensive with event details, patient or device information, and components linked to complaints were not always requested to be returned. You state that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> database has limitations in making updates or corrections to Case Notes details. You have not provided evidence of implementation of corrective actions for these deficiencies. In addition, you have not provided supporting evidence of your CAPA 10308384 to enhance complaint handling\u002FMDR procedures or your CAPA to investigate thermal issues with complaints to determine root cause and if CAPAs will be implemented.\u003C\u002Fp>\u003Cp>3. Failure of design validation to include adequate risk analysis as required by 21 CFR 820.30(g).\u003C\u002Fp>\u003Cp>For example, your firm’s System Hazard Analysis for the MedStation ES System failed to take into consideration higher severity risks such as a complaint reporting a patient death possibly due to delay in accessing medications. In addition, since 2022, there have been multiple reports of life-threatening situations involving Pyxis delay in dispensing medications. For example, complaint 3799113 (system stopped responding during cardiac arrest); 4042263 (users tried to remove required medications to prevent patient from drowning but took too long and patient rushed to hospital); 03842764 (system did not dispense Propofol during a procedure, patient woke up during surgery); 4453386 (wrong CUBIE opened causing significant delay during emergency event, unresponsive patient); 3534347 (patient blood clot and Heparin not showing as available); 4059672 (system did not allow users to remove lorazepam for seizure patient); and 3559647 (system stopped during procedure requiring tracheostomy).\u003C\u002Fp>\u003Cp>Your MedBank System Hazard Analysis identifies five electrical hazards with a severity of harm of Critical or Catastrophic. You stated that all Pyxis systems are IEC 60601 compliant except MedBank because MedBank is not intended for patients as it is used in a pharmacy. You produced a certifying organization (UL) email apparently stating MedBank is a medical device but does not fall within the scope of IEC 60601-1. You stated MedBank falls within IEC 61010, Safety Requirements for Electrical Equipment for Measurement, Control, and Laboratory Use and our investigator noted to you that 61001 pertains to laboratory equipment. There were 8 complaints with electrical issues. You did not provide records to demonstrate that the MedBank devices are compliant with the IEC 60601 standard to ensure that electrical safety hazards are mitigated.\u003C\u002Fp>\u003Cp>Your Pyxis MedStation ES Medication Dispensing system applications allow sharing data and communicating with other systems as described in your Product Risk Management Plan BD Pyxis MedStation ES System. In complaint 4420172, it reported the Pyxis CIISAFE ES system opening the wrong doors for medications after all stations were re-installed after a cyber-attack. You acknowledged that threat modeling procedures have been implemented to assess exploitability of cybersecurity vulnerabilities and possible patient harm. You stated that you conducted \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You have not established a process for assessing the exploitability of cybersecurity vulnerabilities and the severity of patient harm if the vulnerability were to be exploited.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response cannot be determined at this time.\u003C\u002Fp>\u003Cp>You stated that you are taking action through CAPA to ensure risk management files to consider postmarket data. You stated that you have Product Risk Management and Product Risk Management – Released Product procedures but that Product Support Engineers (PSE) are not always included as part of the investigation process. Your Complaint Handling procedure does not require escalation to PSE, and you state that you will enhance the complaint handling and risk management processes. You have not provided evidence of implementation of corrective actions for complaint handling and risk management.\u003C\u002Fp>\u003Cp>For the FDA-cited example, you stated that complaint 2397210 was not escalated but was part of CAPA 3078666 to improve the design history file. You stated that the complaint was considered in the System Hazard Analysis (SHA) from May 7, 2024 but not for what FDA cited, e.g., delayed medication. Per your SHA, the harm severity is Catastrophic. You stated that you have received other complaints to indicate delayed medication hazard and should be Catastrophic. You have not provided evidence of implementation of corrective actions for this harm severity issue.\u003C\u002Fp>\u003Cp>You escalated the threat modeling process and updated security procedures, but it is not evident as to your completion of product security deliverables for the next revision of the Pyxis MedStation ES, review\u002Frevise all product security deliverables for all Dispensing products, and performance of an assessment of the current process to AAMI and FDA guidance documents on cybersecurity to determine whether additional enhancements are required. It is also not evident as to the status of your CAPA 10315457.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection revealed that your firm’s Pyxis devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to submit a report to the FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2). For example:\u003C\u002Fp>\u003Cp>&nbsp; a. The information included for Complaint# 02840390 describes an adverse event occurring as the result of malfunction of your firm’s Pyxis MedStation ES System (i.e. unexpected reboot) while in use. The MDR#2016493-2020-00001 received by FDA describes an event where the patient sustained a serious injury resulting from your firm’s same device malfunction. This report establishes precedence that the referenced malfunction would be likely to cause or contribute to a death or serious injury, if it were to recur. There is no information included for the complaint that justifies that the referenced malfunction would not be likely to cause or contribute to a death or serious injury. Your firm became aware of the event on October 25, 2022. However, the corresponding MDR#2016493-2024-00410 was received by FDA on June 11, 2024, which is beyond the required 30 calendar day timeframe.\u003C\u002Fp>\u003Cp>&nbsp; b. The information included for Complaint# 03595420 describes an adverse event occurring as the result of malfunction of your firm’s Pyxis MedStation ES System (i.e. missing patient data) while in use. The MDR#2016493-2022-99102 received by FDA describes an event where the patient expired as a result of the firm’s same malfunction. This report establishes precedence that the referenced malfunction would be likely to cause or contribute to a death or serious injury, if it were to recur. There is no information included for the complaint that justifies that the referenced malfunction would not be likely to cause or contribute to a death or serious injury. Your firm became aware of the event on June 27, 2023. However, the corresponding MDR#2016493-2024-00415 was received by FDA on June 11, 2024, which is beyond the required 30 calendar day timeframe.\u003C\u002Fp>\u003Cp>&nbsp; c. The information included for Complaint# 02653489 reasonably suggests that your firm’s Pyxis MedStation ES System malfunctioned (i.e. drawer inaccessibility) during use. Your firm had previously initiated recall Z-1015-2013 for the same malfunction. Per the Preamble, in the Medical Devices; Medical User Facility and Manufacturer Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63585 (Dec. 11, 1995), Comment 12, a malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the act as a result of the malfunction of the device or other similar devices. There is no information in the complaint to rule out that the referenced malfunction would not be likely to cause or contribute to a death or serious injury if it were to recur. Your firm became aware of the event on August 29, 2022. However, the corresponding MDR#2016493-2024-00408 was received by FDA on June 11, 2024, which is beyond the required 30 calendar day timeframe.\u003C\u002Fp>\u003Cp>&nbsp; d. The information provided for Complaint #03500083, #03708861, and #04422892 describes malfunctions (i.e. power failure) of your firm’s Pyxis MedBank ES System emitting smoke or burning smell in a hospital setting. We consider the nature of such an oxygen-enriched environment potentiates the possibly of a fire resulting in a death or serious injury if it were to recur. There is no information in the complaints that justified that these events were not the result of a device malfunction. Your firm became aware of Complaint #03500083 on May 25, 2023, Complaint #03708861 on August 3, 2023, and Complaint #04422892 on March 12, 2024, and FDA received the corresponding MDRs #2016493-2024-00400, #2016493-2024-00401, and #2016493-2024-00404 on June 11, 2024, which exceeds the required 30-calendar-day reporting timeframe.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses dated June 13, 2024, July 31, 2024 and September 20, 2024 cannot be determined at this time. In the response, your firm references that it initiated on June 5, 2024, CAPA #10308384 to improve its complaint identification and MDR reporting processes. This includes process and procedural improvements, as well as a transition to its \u003Cstrong>(b)(4)\u003C\u002Fstrong> system for its Pyxis Dispensing products. These are intended to be long-term corrective actions aimed to ensure timely complaint management, MDR assessment, and reporting. Additionally, your firm plans to conduct a retrospective review of complaint records stored in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> electronic tool for cases opened from February 1, 2022 to the present and submit newly identified MDRs. However, your firm has not provided evidence of completing all the planned corrective actions, including the retrospective review of complaint records and staff training.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection also revealed that your firm’s Pyxis devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to submit a Report of Correction or Removal, initiated to remedy a violation which may present a risk to health, within 10 working days of initiating such correction or removal, as required by 21 CFR § 806.10. For example:\u003C\u002Fp>\u003Cp>&nbsp; a. CareFusion issued a Product Advisory, dated 2\u002F14\u002F2023, and a follow-up 1\u002F9\u002F2024, to customers describing three door\u002Fdrawer failure situations, described in MMS-22-4590, MMS-23-4599, and MMS-23-4634. Dispensing system door\u002Fdrawer failure can lead to a delay or inability to dispense medications, which may present a risk to health. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. As of October 31, 2024, you did not submit a Medical Device Report of Correction or Removal to FDA for this action.\u003C\u002Fp>\u003Cp>&nbsp; b. Your firm issued a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, described in MMS-23-4697, for the MedStation ES system software on 3\u002F17\u002F2023. You issued an Urgent Medical Device Correction, dated 4\u002F5\u002F2023, announcing ES 1.7.4 software updates for Alternate Location Tooltip Error and Upload Data Error. Failure of the alternate location tooltip feature for a multi-item order can contribute to a delay in therapy, which may present a risk to health. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. As of October 31, 2024, you did not submit a Medical Device Report of Correction or Removal to FDA for this action.\u003C\u002Fp>\u003Cp>c. CareFusion issued Customer Release Notes dated September 2023, describing BD Pyxis MedBank system release software v1.3.4. This update, described in MMS-23-4884, was intended to resolve the MedBank cabinet allowing dispense of a medication requiring RxVerify Validation Code without the validation code being entered. Dispensing without the validation code could lead to removal and\u002For administration of an incorrect dose, or incorrect medication to a patient, which may present a risk to health. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. As of October 31, 2024, you did not submit a Medical Device Report of Correction or Removal to FDA for this action.\u003C\u002Fp>\u003Cp>Your firm’s response to the FDA-483, dated June 13, 2024, does not address Reports of Corrections or Removals. As of October 31, 2024, you have not submitted Reports of Correction or Removal to FDA for the actions described herein.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to Jeffrey Wooley, Acting Assistant Director at CDRHWarningLetterResponses@fda.hhs.gov. Please include in the subject line, CMS case #691601 when replying. If you have any questions about the contents of this letter, please contact: Raymond W. Brullo, Compliance Officer raymond.brullo@fda.h\u003Ca>hs.gov.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>RDML Sean M. Boyd, MPH, USPHS\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health&nbsp;\u003C\u002Fp>\u003Cp>cc:&nbsp;\u003C\u002Fp>\u003Cp>Connor L. Bates, President, Medication Management Systems at \u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003Cbr>Vipul Sheth, VP of Quality, Medication Management Systems at \u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Thomas E. Polen\n\nRecipient Title\n\nPresident & CEO\n\nBecton, Dickinson, and Company\u002FCareFusion 303, Inc.\n\n1 Becton Drive\n\nFranklin Lakes, NJ 07417\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n11\u002F22\u002F2024\nDear Mr. Polen:\nDuring an inspection of your firm located in San Diego, California on May 6, 2024 through May 22, 2024, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm manufactures Pyxis Medication Management System medical devices including, but not limited to, Pyxis MedStation ES, Pyxis ES Anesthesia, and Pyxis MedBank (hereafter also referred to as Pyxis) Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Vipul Sheth, VP of Quality, MMS dated June 13, 2024 and additional responses dated July 31, 2024 and September 20, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and implement procedures for corrective and preventive actions as required by 21 CFR 820.100(a).\nFor example, you were found to have 544 open tickets for software defects of which 111 were categorized as Catastrophic or Severe patient harm. Four (4) were noted to have\ncybersecurity vulnerabilities. Of 256 open tickets for server software issues, 55 for thermal effects were categorized as Catastrophic or Severe. Your CAPA # 8438925 was not found to be complete.\nThe adequacy of your firm’s response cannot be determined at this time.\nYou provided an Issue and Defect Tracking procedure and stated that closure of “Tickets” will be tracked in a risk-prioritized manner by June 30, 2025 and conduct training. You state that you established a quality metric that monitors the timely closure of “Defects” and presented to the FY2024 Q3 Quarterly Management Review meeting to determine the definition of metric. You have not provided the results of the management review. You also stated you will enhance your (b)(4). You have not provided evidence of implementation of these corrective actions.\n2. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198(a).\nFor example, for 8 complaints [04168007, 04167379, 04170044, 04178943, 04179552, 041686160, 04208805, and 04211537] during the December 2023 to January 2024 time period, for issues with the Pyxis (b)(4) server, e.g., servers offline at three hospitals and required shutdown, none of the complaints were evaluated for MDR reporting. You stated that MDR reportability is not done for (b)(4) server complaints because the server is not a medical device, and that the server is not part of the Pyxis system. Your firm provided evidence of a regulatory assessment as (b)(4) Server Baseline Regulatory Assessment, DIR #10000428322.\nYour firm uses the (b)(4) system to document complaints and has a Complaint Handling Procedure. You also have a Complaint Investigation procedure, but you stated you only perform investigations for MDR reportable complaints. In a review of two spreadsheets, Case Notes for Reportable was noted as N\u002FA. Your firm was found to have approximately 92, 083 complaints for delay in delivery of medications due to freezing, shut down, or malfunction including complaints and 70 complaints for wrong medications dispensed, without evidence of investigation. Also, eight (8) complaints reported potential electrical safety issues with the Pyxis MedBank Dispensing Cabinet, however none were investigated.\nThe adequacy of your firm’s response cannot be determined at this time.\nYou stated that complaint investigations were not comprehensive with event details, patient or device information, and components linked to complaints were not always requested to be returned. You state that your (b)(4) database has limitations in making updates or corrections to Case Notes details. You have not provided evidence of implementation of corrective actions for these deficiencies. In addition, you have not provided supporting evidence of your CAPA 10308384 to enhance complaint handling\u002FMDR procedures or your CAPA to investigate thermal issues with complaints to determine root cause and if CAPAs will be implemented.\n3. Failure of design validation to include adequate risk analysis as required by 21 CFR 820.30(g).\nFor example, your firm’s System Hazard Analysis for the MedStation ES System failed to take into consideration higher severity risks such as a complaint reporting a patient death possibly due to delay in accessing medications. In addition, since 2022, there have been multiple reports of life-threatening situations involving Pyxis delay in dispensing medications. For example, complaint 3799113 (system stopped responding during cardiac arrest); 4042263 (users tried to remove required medications to prevent patient from drowning but took too long and patient rushed to hospital); 03842764 (system did not dispense Propofol during a procedure, patient woke up during surgery); 4453386 (wrong CUBIE opened causing significant delay during emergency event, unresponsive patient); 3534347 (patient blood clot and Heparin not showing as available); 4059672 (system did not allow users to remove lorazepam for seizure patient); and 3559647 (system stopped during procedure requiring tracheostomy).\nYour MedBank System Hazard Analysis identifies five electrical hazards with a severity of harm of Critical or Catastrophic. You stated that all Pyxis systems are IEC 60601 compliant except MedBank because MedBank is not intended for patients as it is used in a pharmacy. You produced a certifying organization (UL) email apparently stating MedBank is a medical device but does not fall within the scope of IEC 60601-1. You stated MedBank falls within IEC 61010, Safety Requirements for Electrical Equipment for Measurement, Control, and Laboratory Use and our investigator noted to you that 61001 pertains to laboratory equipment. There were 8 complaints with electrical issues. You did not provide records to demonstrate that the MedBank devices are compliant with the IEC 60601 standard to ensure that electrical safety hazards are mitigated.\nYour Pyxis MedStation ES Medication Dispensing system applications allow sharing data and communicating with other systems as described in your Product Risk Management Plan BD Pyxis MedStation ES System. In complaint 4420172, it reported the Pyxis CIISAFE ES system opening the wrong doors for medications after all stations were re-installed after a cyber-attack. You acknowledged that threat modeling procedures have been implemented to assess exploitability of cybersecurity vulnerabilities and possible patient harm. You stated that you conducted (b)(4). You have not established a process for assessing the exploitability of cybersecurity vulnerabilities and the severity of patient harm if the vulnerability were to be exploited.\nThe adequacy of your firm’s response cannot be determined at this time.\nYou stated that you are taking action through CAPA to ensure risk management files to consider postmarket data. You stated that you have Product Risk Management and Product Risk Management – Released Product procedures but that Product Support Engineers (PSE) are not always included as part of the investigation process. Your Complaint Handling procedure does not require escalation to PSE, and you state that you will enhance the complaint handling and risk management processes. You have not provided evidence of implementation of corrective actions for complaint handling and risk management.\nFor the FDA-cited example, you stated that complaint 2397210 was not escalated but was part of CAPA 3078666 to improve the design history file. You stated that the complaint was considered in the System Hazard Analysis (SHA) from May 7, 2024 but not for what FDA cited, e.g., delayed medication. Per your SHA, the harm severity is Catastrophic. You stated that you have received other complaints to indicate delayed medication hazard and should be Catastrophic. You have not provided evidence of implementation of corrective actions for this harm severity issue.\nYou escalated the threat modeling process and updated security procedures, but it is not evident as to your completion of product security deliverables for the next revision of the Pyxis MedStation ES, review\u002Frevise all product security deliverables for all Dispensing products, and performance of an assessment of the current process to AAMI and FDA guidance documents on cybersecurity to determine whether additional enhancements are required. It is also not evident as to the status of your CAPA 10315457.\nMedical Device Reporting (MDR)\nOur inspection revealed that your firm’s Pyxis devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Significant violations include, but are not limited to, the following:\n1. Failure to submit a report to the FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets has malfunctioned and this device or a similar device that your firm markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2). For example:\na. The information included for Complaint# 02840390 describes an adverse event occurring as the result of malfunction of your firm’s Pyxis MedStation ES System (i.e. unexpected reboot) while in use. The MDR#2016493-2020-00001 received by FDA describes an event where the patient sustained a serious injury resulting from your firm’s same device malfunction. This report establishes precedence that the referenced malfunction would be likely to cause or contribute to a death or serious injury, if it were to recur. There is no information included for the complaint that justifies that the referenced malfunction would not be likely to cause or contribute to a death or serious injury. Your firm became aware of the event on October 25, 2022. However, the corresponding MDR#2016493-2024-00410 was received by FDA on June 11, 2024, which is beyond the required 30 calendar day timeframe.\nb. The information included for Complaint# 03595420 describes an adverse event occurring as the result of malfunction of your firm’s Pyxis MedStation ES System (i.e. missing patient data) while in use. The MDR#2016493-2022-99102 received by FDA describes an event where the patient expired as a result of the firm’s same malfunction. This report establishes precedence that the referenced malfunction would be likely to cause or contribute to a death or serious injury, if it were to recur. There is no information included for the complaint that justifies that the referenced malfunction would not be likely to cause or contribute to a death or serious injury. Your firm became aware of the event on June 27, 2023. However, the corresponding MDR#2016493-2024-00415 was received by FDA on June 11, 2024, which is beyond the required 30 calendar day timeframe.\nc. The information included for Complaint# 02653489 reasonably suggests that your firm’s Pyxis MedStation ES System malfunctioned (i.e. drawer inaccessibility) during use. Your firm had previously initiated recall Z-1015-2013 for the same malfunction. Per the Preamble, in the Medical Devices; Medical User Facility and Manufacturer Reporting, Certification and Registration; Final Rule, 60 Fed. Reg. 63585 (Dec. 11, 1995), Comment 12, a malfunction is reportable if the manufacturer takes or would be required to take an action under sections 518 or 519(g) of the act as a result of the malfunction of the device or other similar devices. There is no information in the complaint to rule out that the referenced malfunction would not be likely to cause or contribute to a death or serious injury if it were to recur. Your firm became aware of the event on August 29, 2022. However, the corresponding MDR#2016493-2024-00408 was received by FDA on June 11, 2024, which is beyond the required 30 calendar day timeframe.\nd. The information provided for Complaint #03500083, #03708861, and #04422892 describes malfunctions (i.e. power failure) of your firm’s Pyxis MedBank ES System emitting smoke or burning smell in a hospital setting. We consider the nature of such an oxygen-enriched environment potentiates the possibly of a fire resulting in a death or serious injury if it were to recur. There is no information in the complaints that justified that these events were not the result of a device malfunction. Your firm became aware of Complaint #03500083 on May 25, 2023, Complaint #03708861 on August 3, 2023, and Complaint #04422892 on March 12, 2024, and FDA received the corresponding MDRs #2016493-2024-00400, #2016493-2024-00401, and #2016493-2024-00404 on June 11, 2024, which exceeds the required 30-calendar-day reporting timeframe.\nThe adequacy of your firm’s responses dated June 13, 2024, July 31, 2024 and September 20, 2024 cannot be determined at this time. In the response, your firm references that it initiated on June 5, 2024, CAPA #10308384 to improve its complaint identification and MDR reporting processes. This includes process and procedural improvements, as well as a transition to its (b)(4) system for its Pyxis Dispensing products. These are intended to be long-term corrective actions aimed to ensure timely complaint management, MDR assessment, and reporting. Additionally, your firm plans to conduct a retrospective review of complaint records stored in the (b)(4) electronic tool for cases opened from February 1, 2022 to the present and submit newly identified MDRs. However, your firm has not provided evidence of completing all the planned corrective actions, including the retrospective review of complaint records and staff training.\nCorrections and Removals\nOur inspection also revealed that your firm’s Pyxis devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Violations include, but are not limited to, the following:\n1. Failure to submit a Report of Correction or Removal, initiated to remedy a violation which may present a risk to health, within 10 working days of initiating such correction or removal, as required by 21 CFR § 806.10. For example:\na. CareFusion issued a Product Advisory, dated 2\u002F14\u002F2023, and a follow-up 1\u002F9\u002F2024, to customers describing three door\u002Fdrawer failure situations, described in MMS-22-4590, MMS-23-4599, and MMS-23-4634. Dispensing system door\u002Fdrawer failure can lead to a delay or inability to dispense medications, which may present a risk to health. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. As of October 31, 2024, you did not submit a Medical Device Report of Correction or Removal to FDA for this action.\nb. Your firm issued a (b)(4), described in MMS-23-4697, for the MedStation ES system software on 3\u002F17\u002F2023. You issued an Urgent Medical Device Correction, dated 4\u002F5\u002F2023, announcing ES 1.7.4 software updates for Alternate Location Tooltip Error and Upload Data Error. Failure of the alternate location tooltip feature for a multi-item order can contribute to a delay in therapy, which may present a risk to health. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. As of October 31, 2024, you did not submit a Medical Device Report of Correction or Removal to FDA for this action.\nc. CareFusion issued Customer Release Notes dated September 2023, describing BD Pyxis MedBank system release software v1.3.4. This update, described in MMS-23-4884, was intended to resolve the MedBank cabinet allowing dispense of a medication requiring RxVerify Validation Code without the validation code being entered. Dispensing without the validation code could lead to removal and\u002For administration of an incorrect dose, or incorrect medication to a patient, which may present a risk to health. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. As of October 31, 2024, you did not submit a Medical Device Report of Correction or Removal to FDA for this action.\nYour firm’s response to the FDA-483, dated June 13, 2024, does not address Reports of Corrections or Removals. As of October 31, 2024, you have not submitted Reports of Correction or Removal to FDA for the actions described herein.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to Jeffrey Wooley, Acting Assistant Director at CDRHWarningLetterResponses@fda.hhs.gov. Please include in the subject line, CMS case #691601 when replying. If you have any questions about the contents of this letter, please contact: Raymond W. Brullo, Compliance Officer raymond.brullo@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nRDML Sean M. Boyd, MPH, USPHS\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\ncc:\nConnor L. Bates, President, Medication Management Systems at (b)(6)\nVipul Sheth, VP of Quality, Medication Management Systems at (b)(6)","Becton, Dickinson, and Company\u002FCareFusion 303, Inc.","becton-dickinson-and-companycarefusion-303-inc-691601-11222024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbecton-dickinson-and-companycarefusion-303-inc-691601-11222024","2026-10-26T08:08:02.648403+00:00","2024-12-17","691601","Medical Devices","Mr. Thomas E. Polen","2026-08-19T17:07:52.992+00:00","2024-11-22",3,{"510k":78,"classification":79,"enforcement":80,"event":81,"event_backfill":82,"pma":83,"warning_letter":84},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]